[
  {
    "ts": null,
    "headline": "FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX)",
    "summary": "Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first quarter of 2026 for use in multiple imaging procedures. This marks a significant entry into a US$652 million market and expands Amneal's offering of complex injectable pharmaceuticals, targeting both adult and pediatric patient populations. We'll explore how FDA approval of Amneal's first-to-market...",
    "url": "https://finnhub.io/api/news?id=748744b60baba04bc8de3ecfe26e91b9020246bebf49d2bb839ec4e245e08387",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763194586,
      "headline": "FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX)",
      "id": 137494882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first quarter of 2026 for use in multiple imaging procedures. This marks a significant entry into a US$652 million market and expands Amneal's offering of complex injectable pharmaceuticals, targeting both adult and pediatric patient populations. We'll explore how FDA approval of Amneal's first-to-market...",
      "url": "https://finnhub.io/api/news?id=748744b60baba04bc8de3ecfe26e91b9020246bebf49d2bb839ec4e245e08387"
    }
  }
]